Source-grounded facts extracted from Lexeo Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Lexeo Therapeutics, Inc. reported the first quarter 2026 results: net income Net loss was $20.2 million or $0.25 per share (basic and diluted) for the three months ended March 31, 2026, EPS $0.25 per share (basic and diluted).
“Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights”
Dr. Laura Sepp-Lorenzino was appointed as Director at Lexeo Therapeutics, Inc..
“On April 28, 2026 (the “ Appointment Date ”), Dr. Laura Sepp-Lorenzino was appointed to the board of directors (the “ Board ”) of Lexeo Therapeutics, Inc.”
Lexeo Therapeutics, Inc. reported financial results for the fourth quarter and full year 2025.
“On March 30, 2026, Lexeo Therapeutics, Inc. (the “ Company ”) issued a press release announcing business highlights and its financial results for the three and twelve months ended December 31, 2025.”
Tolga Tanguler was appointed as director at Lexeo Therapeutics, Inc..
“On November 11, 2024 (the “ Appointment Date ”), Tolga Tanguler was appointed to the board of directors of the Company (the “ Board ”).”
Tim Van Hauwermeiren was appointed as Director at Lexeo Therapeutics, Inc..
“On July 5, 2024 (the “Appointment Date”), Tim Van Hauwermeiren was appointed to the board of directors (the “Board”) of Lexeo Therapeutics, Inc. (the “Company”).”
Lexeo Therapeutics, Inc. reported first quarter 2024 results: net income $21.7 million or $0.77 per share (basic and diluted), EPS $0.77 per share (basic and diluted).
“Net loss was $21.7 million or $0.77 per share (basic and diluted) for the three months ended March 31, 2024”
Lexeo Therapeutics, Inc. entered into Third License Agreement with Cornell University valued at $600,000 (effective 2024-04-21).
“On April 21, 2024, Lexeo Therapeutics, Inc. (the “Company”) entered into the Third License Agreement (the “License Agreement”) with Cornell University”
Bernard Davitian departed as Director at Lexeo Therapeutics, Inc..
“On April 16, 2024, Bernard Davitian notified Lexeo Therapeutics, Inc. (the “Company”) that he does not intend to stand for reelection at the Company’s 2024 annual meeting of stockholders on June 25, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.